---
title: "Descartes-08 in Generalized myasthenia gravis: Long-term morbidity"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Long-term morbidity. Topics: Myasthenic crisis: frequency, triggers, and outcomes; Myasthenic crisis: Ontario, Canada, population-based incidence; Exacerbations and crises: predictors, United States generalized myasthenia gravis; Refractory disease: persistent moderate or severe weakness; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Myasthenic crisis: frequency, triggers, and outcomes

> “Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.”
> “MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.”
> “Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.”
> “MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.”
> “The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.”

Source: [Claytor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114503/)

> “A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks”
> “Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-2"></a>

### Myasthenic crisis: Ontario, Canada, population-based incidence

> “Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.7-3"></a>

### Exacerbations and crises: predictors, United States generalized myasthenia gravis

> “Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.7-4"></a>

### Refractory disease: persistent moderate or severe weakness

> “However, 10%–20% of patients continue to have long‐standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.7-5"></a>

### Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis

> “Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).”
> “During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001”
> “Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).”
> “Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)”
> “Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.7-6"></a>

### Glucocorticoid toxicity: recognized adverse effects and higher-risk patients

> “However, long-term use of GCs is associated with potentially serious toxicities, including weight gain, cataracts, hypertension, diabetes, osteoporosis, infections, and neuropsychiatric symptoms”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

> “MG patients with osteoporosis, obesity, diabetes, and mental disorders have a particularly high risk of corticosteroid side effects.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.1.7-7"></a>

### Refractory disease: share and crisis rates in U.S. administrative health plan data

> “Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases.”
> “Compared with nonrefractory patients, a significantly greater percentage of refractory patients had at least one myasthenic crisis (21.3% vs. 6.1%; P < 0.001) and at least one exacerbation (71.2% vs. 32.4%; P < 0.001) over a 1-year period.”

Source: [Engel-Nitz et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29486521/)

<a id="topic-2.2.1.7-8"></a>

### Refractory disease: share and characteristics in a U.S. tertiary neuromuscular clinic, 2003 to 2011

> “A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011.”
> “Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.”

Source: [Suh et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3670444/)

<a id="topic-2.2.1.7-9"></a>

### Refractory disease: share assumed in the ICER evaluation

> “The population with gMG is 14-20 per 100,000, and if only 15% of this population is considered to have refractory gMG, the population now eligible for treatment with eculizumab is more than seven times as large as when the drug was first approved, yet the price has not come down.”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-2.2.1.7-10"></a>

### Persistently uncontrolled disease over 8 years of follow-up: Spanish referral cohort

> “The proportion adequately controlled (AC) patients increased from 62.0% at 2 years after first visit to 81.9% after 8 years of follow-up. 47.3% of patients remained AC in every observation, and 17.7% remained not adequately controlled (NC) in every observation.”
> “AE-related drug interruption rates were higher in NC patients (ranging from 50% to 100% during the study).”

Source: [Reyes-Leiva et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13714894/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
